Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Interleukin-33 (IL-33), a member of the interleukin-1(IL-1) family of cytokines, remains poorly understood in the context of human breast cancer and its impact on treatment outcomes. This study aimed to elucidate IL-33 expression patterns within tumor samples from a cohort of Brazilian female breast...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/22/16326 |
| _version_ | 1797458999011966976 |
|---|---|
| author | Renata B. Albuquerque Maria Amélia S. M. Borba Matheus S. S. Fernandes Tayrine O. Filgueira Danyelly Bruneska G. Martins José Luiz L. Filho Angela Castoldi Fabrício Oliveira Souto |
| author_facet | Renata B. Albuquerque Maria Amélia S. M. Borba Matheus S. S. Fernandes Tayrine O. Filgueira Danyelly Bruneska G. Martins José Luiz L. Filho Angela Castoldi Fabrício Oliveira Souto |
| author_sort | Renata B. Albuquerque |
| collection | DOAJ |
| description | Interleukin-33 (IL-33), a member of the interleukin-1(IL-1) family of cytokines, remains poorly understood in the context of human breast cancer and its impact on treatment outcomes. This study aimed to elucidate IL-33 expression patterns within tumor samples from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy while exploring its correlation with clinicopathological markers. In total, 68 samples were meticulously evaluated, with IL-33 expression quantified through a quantitative polymerase chain reaction. The findings revealed a substantial upregulation of IL-33 expression in breast cancer patient samples, specifically within the Triple-negative and Luminal A and B subtypes, when compared to controls (healthy breast tissues). Notably, the Luminal B subtype displayed a marked elevation in IL-33 expression relative to the Luminal A subtype (<i>p</i> < 0.05). Moreover, a progressive surge in IL-33 expression was discerned among Luminal subtype patients with TNM 4 staging criteria, further underscoring its significance (<i>p</i> < 0.005). Furthermore, chemotherapy-naïve patients of Luminal A and B subtypes exhibited heightened IL-33 expression (<i>p</i> < 0.05). Collectively, our findings propose that chemotherapy could potentially mitigate tumor aggressiveness by suppressing IL-33 expression in breast cancer, thus warranting consideration as a prognostic marker for gauging chemotherapy response and predicting disease progression in Luminal subtype patients. This study not only sheds light on the intricate roles of IL-33 in breast cancer but also offers valuable insights for future IL-33-related research endeavors within this context. |
| first_indexed | 2024-03-09T16:45:13Z |
| format | Article |
| id | doaj.art-a1473ad0cc4b4a6f96d93dcc24dc38cf |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T16:45:13Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a1473ad0cc4b4a6f96d93dcc24dc38cf2023-11-24T14:47:10ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-11-0124221632610.3390/ijms242216326Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant ChemotherapyRenata B. Albuquerque0Maria Amélia S. M. Borba1Matheus S. S. Fernandes2Tayrine O. Filgueira3Danyelly Bruneska G. Martins4José Luiz L. Filho5Angela Castoldi6Fabrício Oliveira Souto7Keizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilKeizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilPostgraduate Program in Neuropsychiatry and Behavioral Sciences, Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilKeizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilKeizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilKeizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilKeizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilKeizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego s/n, Recife 50670-901, PE, BrazilInterleukin-33 (IL-33), a member of the interleukin-1(IL-1) family of cytokines, remains poorly understood in the context of human breast cancer and its impact on treatment outcomes. This study aimed to elucidate IL-33 expression patterns within tumor samples from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy while exploring its correlation with clinicopathological markers. In total, 68 samples were meticulously evaluated, with IL-33 expression quantified through a quantitative polymerase chain reaction. The findings revealed a substantial upregulation of IL-33 expression in breast cancer patient samples, specifically within the Triple-negative and Luminal A and B subtypes, when compared to controls (healthy breast tissues). Notably, the Luminal B subtype displayed a marked elevation in IL-33 expression relative to the Luminal A subtype (<i>p</i> < 0.05). Moreover, a progressive surge in IL-33 expression was discerned among Luminal subtype patients with TNM 4 staging criteria, further underscoring its significance (<i>p</i> < 0.005). Furthermore, chemotherapy-naïve patients of Luminal A and B subtypes exhibited heightened IL-33 expression (<i>p</i> < 0.05). Collectively, our findings propose that chemotherapy could potentially mitigate tumor aggressiveness by suppressing IL-33 expression in breast cancer, thus warranting consideration as a prognostic marker for gauging chemotherapy response and predicting disease progression in Luminal subtype patients. This study not only sheds light on the intricate roles of IL-33 in breast cancer but also offers valuable insights for future IL-33-related research endeavors within this context.https://www.mdpi.com/1422-0067/24/22/16326interleukin-33breast cancerluminal subtype |
| spellingShingle | Renata B. Albuquerque Maria Amélia S. M. Borba Matheus S. S. Fernandes Tayrine O. Filgueira Danyelly Bruneska G. Martins José Luiz L. Filho Angela Castoldi Fabrício Oliveira Souto Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy International Journal of Molecular Sciences interleukin-33 breast cancer luminal subtype |
| title | Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
| title_full | Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
| title_fullStr | Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
| title_full_unstemmed | Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
| title_short | Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
| title_sort | interleukin 33 expression on treatment outcomes and prognosis in brazilian breast cancer patients undergoing neoadjuvant chemotherapy |
| topic | interleukin-33 breast cancer luminal subtype |
| url | https://www.mdpi.com/1422-0067/24/22/16326 |
| work_keys_str_mv | AT renatabalbuquerque interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT mariaameliasmborba interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT matheusssfernandes interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT tayrineofilgueira interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT danyellybruneskagmartins interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT joseluizlfilho interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT angelacastoldi interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy AT fabriciooliveirasouto interleukin33expressionontreatmentoutcomesandprognosisinbrazilianbreastcancerpatientsundergoingneoadjuvantchemotherapy |